|Mr. Jonathan P. Mow||Pres, CEO & Director||561.1k||N/A||1965|
|Mr. John P. Sharp||Chief Financial Officer||451.62k||N/A||1965|
|Dr. John S. Lee||Chief Medical Officer||473.43k||N/A||1968|
|Mr. Kristopher L. Hanson||VP & Head of Legal||N/A||N/A||N/A|
|Mr. Michael B. York||VP of Corp. Devel. & Commercial Strategy||N/A||N/A||1965|
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. The company is also developing PB1046, a fusion protein that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.
PhaseBio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 9.